Cargando…

Critical appraisal of bevacizumab in the treatment of ovarian cancer

Bevacizumab is the first molecular-targeted agent to be used for the treatment of ovarian cancer. Bevacizumab is a humanized monoclonal antibody targeting vascular endothelial growth factor. Two randomized Phase III trials evaluated the combination of bevacizumab plus standard cytotoxic chemotherapy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Hiroyuki, Yabuno, Akira, Fujiwara, Keiichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4423500/ https://www.ncbi.nlm.nih.gov/pubmed/25960638 http://dx.doi.org/10.2147/DDDT.S83275

Ejemplares similares

Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer
por: Zoratto, Federica, et al.
Publicado: (2012)

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma
por: Sato, Masakazu, et al.
Publicado: (2022)

Bevacizumab in ovarian cancer: A critical review of phase III studies
por: Rossi, Luigi, et al.
Publicado: (2016)

Evaluation of Circulating Tumor DNA in Patients with Ovarian Cancer Harboring Somatic PIK3CA or KRAS Mutations
por: Ogasawara, Aiko, et al.
Publicado: (2020)

Critical appraisal of trastuzumab in treatment of advanced stomach cancer
por: Meza-Junco, Judith, et al.
Publicado: (2011)

Adipose tissue area is a predictive biomarker for the efficacy of pegylated liposomal doxorubicin in platinum‐refractory/resistant ovarian cancer
por: Yoshida, Hiroyuki, et al.
Publicado: (2023)

High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo
por: Ikeda, Yuji, et al.
Publicado: (2020)

Critical appraisal of ramelteon in the treatment of insomnia
por: Mets, Monique AJ, et al.
Publicado: (2010)

The Bologna criteria for poor ovarian response: a contemporary critical appraisal
por: Younis, Johnny S., et al.
Publicado: (2015)

Critical appraisal of paroxetine for the treatment of vasomotor symptoms
por: Carroll, Dana G, et al.
Publicado: (2015)

Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives
por: McClung, E Clair, et al.
Publicado: (2016)

First-line treatment of women with advanced ovarian cancer: focus on bevacizumab
por: Marchetti, Claudia, et al.
Publicado: (2019)

Current status of bevacizumab in advanced ovarian cancer
por: Tomao, Federica, et al.
Publicado: (2013)

Association between effector-type regulatory T cells and immune checkpoint expression on CD8(+) T cells in malignant ascites from epithelial ovarian cancer
por: Sato, Sho, et al.
Publicado: (2022)

Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m(2) versus 40 mg/m(2) in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial
por: Motohashi, Takashi, et al.
Publicado: (2020)

Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial
por: Fujiwara, Keiichi, et al.
Publicado: (2021)

Perforated gastric cancer: a critical appraisal
por: Di Carlo, Sara, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review
por: Aravantinos, Gerasimos, et al.
Publicado: (2014)

A pilot study of mobile digital colposcopy in Japanese patients with cervical intraepithelial neoplasm
por: Sato, Masakazu, et al.
Publicado: (2021)

Bevacizumab in combination with chemotherapy in platinum-sensitive ovarian cancer
por: Della Pepa, Chiara, et al.
Publicado: (2014)

Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis
por: Warnke, Clemens, et al.
Publicado: (2011)

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS
por: Pandey, Krishan K
Publicado: (2014)

Critical appraisal of bilastine for the treatment of allergic rhinoconjunctivitis and urticaria
por: Sadaba, Belen, et al.
Publicado: (2013)

Critical appraisal of ranibizumab in the treatment of diabetic macular edema
por: Stewart, Michael W
Publicado: (2013)

Bevacizumab in combination with gemcitabine and carboplatin in recurrent ovarian cancer: a critical consideration
por: Giovannoni, Sara, et al.
Publicado: (2014)

Bevacizumab Treatment for Low-Grade Serous Ovarian Cancer: A Systematic Review
por: Lazurko, Caitlin, et al.
Publicado: (2023)

Critical appraisal of cabazitaxel in the management of advanced prostate cancer
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Critical appraisal of the use of regorafenib in the management of colorectal cancer
por: Festino, Lucia, et al.
Publicado: (2013)

Critical appraisal of the potential use of cannabinoids in cancer management
por: Cridge, Belinda J, et al.
Publicado: (2013)

Management of Patients with Treatment of Pheochromocytoma: A Critical Appraisal
por: Bihain, Florence, et al.
Publicado: (2022)

Critical appraisal of Doshavaha Srotas
por: Byadgi, Parameswarappa S.
Publicado: (2012)

Critical appraisal of published literature
por: Umesh, Goneppanavar, et al.
Publicado: (2016)

Critical appraisal of rituximab in the maintenance treatment of advanced follicular lymphoma
por: Aguiar-Bujanda, David, et al.
Publicado: (2015)

Critical appraisal of tocilizumab in the treatment of moderate to severe rheumatoid arthritis
por: Hushaw, Linda L, et al.
Publicado: (2010)

Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal
por: Cesareo, Roberto, et al.
Publicado: (2010)

Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia
por: DeRemer, David L, et al.
Publicado: (2011)

Critical appraisal of the Spanner™ prostatic stent in the treatment of prostatic obstruction
por: McKenzie, Patrick, et al.
Publicado: (2011)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5os6dvq2fn4u9flekr94v55tdp